eduKateSG · Why Science?
Use deep biological characterisation to select a practical set of identity, purity, potency and quantity tests for routine control
Read FDA’s final August 1999 ICH Q6B guidance through physicochemical characterisation, biological activity, immunochemical properties, product-related substances, process-related impurities, reference standards and justified specifications.
A biological product is rarely one perfectly uniform molecule. Glycoforms, charge variants, clipped forms, aggregates and other related species can coexist, so a useful specification begins with deep characterisation of what the product is.
FDA’s final August 1999 ICH Q6B guidance provides principles for setting and justifying specifications for biotechnological and biological products in new marketing applications.
Did you know? Characterisation and routine specifications have different jobs. Characterisation uses a broad scientific toolkit to understand the product, while the specification selects a smaller set of tests that can control routine batches.
For students, Q6B is the art of compressing complex molecular knowledge into dependable release decisions without pretending the biology is simpler than it is.
Chapter index
Chapters 1–9: August 1999 final guidance, biological-product characterisation and specifications
- 1. Q6B addresses biotechnology and biological products
- 2. The August 1999 FDA guidance is final
- 3. Characterisation creates the knowledge base
- 4. Identity confirms the intended biological product
- 5. Physicochemical characterisation reveals molecular form
- 6. Biological activity connects molecule to function
- 7. Immunochemical properties can support identity and function
- 8. Product-related substances can retain desired activity
- 9. Product-related impurities differ in quality impact
Chapters 10–17: identity, purity, impurities, potency, quantity, reference standards, process capability and stability
- 10. Process-related impurities follow the manufacturing system
- 11. Purity needs multiple analytical views
- 12. Reference standards anchor continuity
- 13. Quantity and protein content support dosing and consistency
- 14. Specifications follow characterisation, process and clinical knowledge
- 15. Release and shelf-life criteria can reflect change over time
- 16. Process changes can alter biological attributes
- 17. A complete Q6B receipt connects complexity to control
CHAPTER 1 OF 17 · Characterise deeply
1. Q6B addresses biotechnology and biological products
The guidance supports uniform international specifications for biological products and recognises their structural complexity, heterogeneity and strong dependence on the manufacturing process.
The scientific value of q6b addresses biotechnology and biological products comes from linking knowledge to a defined quality decision. The guidance supports uniform international specifications for biological products and recognises their structural complexity, heterogeneity and strong dependence on the manufacturing process. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
Try this
Build an evidence map for q6b addresses biotechnology and biological products. Trace q6b addresses biotechnology and biological products from molecular or process origin to its safety or efficacy relevance. Add the decision, owner and acceptance criterion. Keep this limit: A single purity method cannot describe every relevant biological variant.
A strong science note separates observation from interpretation. Trace q6b addresses biotechnology and biological products from molecular or process origin to its safety or efficacy relevance. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace q6b addresses biotechnology and biological products from molecular or process origin to its safety or efficacy relevance. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
FDA lists Q6B as final guidance and provides an official document covering principles, analytical considerations, specifications and impurity terminology.
For the august 1999 fda guidance is final, a useful explanation shows both expected performance and the response to variation. FDA lists Q6B as final guidance and provides an official document covering principles, analytical considerations, specifications and impurity terminology. Preserve this guardrail: Binding activity may not substitute for a functional potency assay when function matters.
Try this
Challenge the assumptions behind the august 1999 fda guidance is final. Use an orthogonal method or functional assay to challenge the august 1999 fda guidance is final. Test a plausible failure mode and record the result. Respect this boundary: Binding activity may not substitute for a functional potency assay when function matters.
A strong science note separates observation from interpretation. Use an orthogonal method or functional assay to challenge the august 1999 fda guidance is final. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Use an orthogonal method or functional assay to challenge the august 1999 fda guidance is final. Keep this boundary visible: Binding activity may not substitute for a functional potency assay when function matters.
Primary and higher-order structure, physicochemical properties, biological activity, immunochemical properties, purity and impurities are studied with suitable techniques.
A trustworthy account of characterisation creates the knowledge base keeps evidence, assumptions and lifecycle action together. Primary and higher-order structure, physicochemical properties, biological activity, immunochemical properties, purity and impurities are studied with suitable techniques. Remember: Manufacturing consistency alone does not prove every product-related variant is acceptable.
Try this
Audit the lifecycle record for characterisation creates the knowledge base. Justify the acceptance criterion for characterisation creates the knowledge base using batches, process capability and clinical knowledge. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Manufacturing consistency alone does not prove every product-related variant is acceptable.
A strong science note separates observation from interpretation. Justify the acceptance criterion for characterisation creates the knowledge base using batches, process capability and clinical knowledge. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Justify the acceptance criterion for characterisation creates the knowledge base using batches, process capability and clinical knowledge. Keep this boundary visible: Manufacturing consistency alone does not prove every product-related variant is acceptable.
CHAPTER 4 OF 17 · Characterise deeply
4. Identity confirms the intended biological product
Peptide mapping, sequence, immunochemical, physicochemical or functional tests can contribute. The routine identity strategy should discriminate the product from plausible alternatives.
The scientific value of identity confirms the intended biological product comes from linking knowledge to a defined quality decision. Peptide mapping, sequence, immunochemical, physicochemical or functional tests can contribute. The routine identity strategy should discriminate the product from plausible alternatives. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
Try this
Build an evidence map for identity confirms the intended biological product. Reassess identity confirms the intended biological product after a cell, process, formulation or reference-standard change. Add the decision, owner and acceptance criterion. Keep this limit: Routine specifications cannot replace broad characterisation during development and change assessment.
A strong science note separates observation from interpretation. Reassess identity confirms the intended biological product after a cell, process, formulation or reference-standard change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess identity confirms the intended biological product after a cell, process, formulation or reference-standard change. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
CHAPTER 5 OF 17 · Select meaningful tests
5. Physicochemical characterisation reveals molecular form
Mass, composition, charge, size, folding, glycosylation and other modifications may be relevant. Orthogonal methods reduce reliance on one measurement principle.
For physicochemical characterisation reveals molecular form, a useful explanation shows both expected performance and the response to variation. Mass, composition, charge, size, folding, glycosylation and other modifications may be relevant. Orthogonal methods reduce reliance on one measurement principle. Preserve this guardrail: A single purity method cannot describe every relevant biological variant.
Try this
Challenge the assumptions behind physicochemical characterisation reveals molecular form. Trace physicochemical characterisation reveals molecular form from molecular or process origin to its safety or efficacy relevance. Test a plausible failure mode and record the result. Respect this boundary: A single purity method cannot describe every relevant biological variant.
A strong science note separates observation from interpretation. Trace physicochemical characterisation reveals molecular form from molecular or process origin to its safety or efficacy relevance. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace physicochemical characterisation reveals molecular form from molecular or process origin to its safety or efficacy relevance. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
CHAPTER 6 OF 17 · Select meaningful tests
6. Biological activity connects molecule to function
Cell-based or biochemical assays measure a relevant functional response. Potency methods need suitable accuracy, precision, range, reference systems and control of biological variability.
A trustworthy account of biological activity connects molecule to function keeps evidence, assumptions and lifecycle action together. Cell-based or biochemical assays measure a relevant functional response. Potency methods need suitable accuracy, precision, range, reference systems and control of biological variability. Remember: Binding activity may not substitute for a functional potency assay when function matters.
Try this
Audit the lifecycle record for biological activity connects molecule to function. Use an orthogonal method or functional assay to challenge biological activity connects molecule to function. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Binding activity may not substitute for a functional potency assay when function matters.
A strong science note separates observation from interpretation. Use an orthogonal method or functional assay to challenge biological activity connects molecule to function. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Use an orthogonal method or functional assay to challenge biological activity connects molecule to function. Keep this boundary visible: Binding activity may not substitute for a functional potency assay when function matters.
CHAPTER 7 OF 17 · Select meaningful tests
7. Immunochemical properties can support identity and function
Binding to antibodies, antigens or receptors may provide useful evidence. Binding alone may not represent the complete mechanism of action.
The scientific value of immunochemical properties can support identity and function comes from linking knowledge to a defined quality decision. Binding to antibodies, antigens or receptors may provide useful evidence. Binding alone may not represent the complete mechanism of action. Keep this boundary visible: Manufacturing consistency alone does not prove every product-related variant is acceptable.
Try this
Build an evidence map for immunochemical properties can support identity and function. Justify the acceptance criterion for immunochemical properties can support identity and function using batches, process capability and clinical knowledge. Add the decision, owner and acceptance criterion. Keep this limit: Manufacturing consistency alone does not prove every product-related variant is acceptable.
A strong science note separates observation from interpretation. Justify the acceptance criterion for immunochemical properties can support identity and function using batches, process capability and clinical knowledge. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Justify the acceptance criterion for immunochemical properties can support identity and function using batches, process capability and clinical knowledge. Keep this boundary visible: Manufacturing consistency alone does not prove every product-related variant is acceptable.
CHAPTER 8 OF 17 · Select meaningful tests
8. Product-related substances can retain desired activity
Molecular variants may have properties comparable to the desired product and can be considered product-related substances when scientifically justified.
For product-related substances can retain desired activity, a useful explanation shows both expected performance and the response to variation. Molecular variants may have properties comparable to the desired product and can be considered product-related substances when scientifically justified. Preserve this guardrail: Routine specifications cannot replace broad characterisation during development and change assessment.
Try this
Challenge the assumptions behind product-related substances can retain desired activity. Reassess product-related substances can retain desired activity after a cell, process, formulation or reference-standard change. Test a plausible failure mode and record the result. Respect this boundary: Routine specifications cannot replace broad characterisation during development and change assessment.
A strong science note separates observation from interpretation. Reassess product-related substances can retain desired activity after a cell, process, formulation or reference-standard change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess product-related substances can retain desired activity after a cell, process, formulation or reference-standard change. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
CHAPTER 9 OF 17 · Set justified criteria
9. Product-related impurities differ in quality impact
Variants such as aggregates, fragments or altered forms may lack desired properties or introduce risk. Their origin, activity and stability inform control.
A trustworthy account of product-related impurities differ in quality impact keeps evidence, assumptions and lifecycle action together. Variants such as aggregates, fragments or altered forms may lack desired properties or introduce risk. Their origin, activity and stability inform control. Remember: A single purity method cannot describe every relevant biological variant.
Try this
Audit the lifecycle record for product-related impurities differ in quality impact. Trace product-related impurities differ in quality impact from molecular or process origin to its safety or efficacy relevance. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: A single purity method cannot describe every relevant biological variant.
A strong science note separates observation from interpretation. Trace product-related impurities differ in quality impact from molecular or process origin to its safety or efficacy relevance. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace product-related impurities differ in quality impact from molecular or process origin to its safety or efficacy relevance. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
CHAPTER 10 OF 17 · Set justified criteria
10. Process-related impurities follow the manufacturing system
Host-cell proteins, host-cell DNA, media components, reagents, enzymes, ligands and leachables can remain from production. Process clearance and sensitive tests support limits.
The scientific value of process-related impurities follow the manufacturing system comes from linking knowledge to a defined quality decision. Host-cell proteins, host-cell DNA, media components, reagents, enzymes, ligands and leachables can remain from production. Process clearance and sensitive tests support limits. Keep this boundary visible: Binding activity may not substitute for a functional potency assay when function matters.
Try this
Build an evidence map for process-related impurities follow the manufacturing system. Use an orthogonal method or functional assay to challenge process-related impurities follow the manufacturing system. Add the decision, owner and acceptance criterion. Keep this limit: Binding activity may not substitute for a functional potency assay when function matters.
A strong science note separates observation from interpretation. Use an orthogonal method or functional assay to challenge process-related impurities follow the manufacturing system. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Use an orthogonal method or functional assay to challenge process-related impurities follow the manufacturing system. Keep this boundary visible: Binding activity may not substitute for a functional potency assay when function matters.
Size-exclusion, electrophoretic, chromatographic, mass-spectrometric and other methods reveal different species. A single purity percentage can hide important heterogeneity.
For purity needs multiple analytical views, a useful explanation shows both expected performance and the response to variation. Size-exclusion, electrophoretic, chromatographic, mass-spectrometric and other methods reveal different species. A single purity percentage can hide important heterogeneity. Preserve this guardrail: Manufacturing consistency alone does not prove every product-related variant is acceptable.
Try this
Challenge the assumptions behind purity needs multiple analytical views. Justify the acceptance criterion for purity needs multiple analytical views using batches, process capability and clinical knowledge. Test a plausible failure mode and record the result. Respect this boundary: Manufacturing consistency alone does not prove every product-related variant is acceptable.
A strong science note separates observation from interpretation. Justify the acceptance criterion for purity needs multiple analytical views using batches, process capability and clinical knowledge. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Justify the acceptance criterion for purity needs multiple analytical views using batches, process capability and clinical knowledge. Keep this boundary visible: Manufacturing consistency alone does not prove every product-related variant is acceptable.
Primary and working standards support identity, potency and other assays. Qualification, storage, monitoring and replacement bridging prevent reference drift.
A trustworthy account of reference standards anchor continuity keeps evidence, assumptions and lifecycle action together. Primary and working standards support identity, potency and other assays. Qualification, storage, monitoring and replacement bridging prevent reference drift. Remember: Routine specifications cannot replace broad characterisation during development and change assessment.
Try this
Audit the lifecycle record for reference standards anchor continuity. Reassess reference standards anchor continuity after a cell, process, formulation or reference-standard change. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Routine specifications cannot replace broad characterisation during development and change assessment.
A strong science note separates observation from interpretation. Reassess reference standards anchor continuity after a cell, process, formulation or reference-standard change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess reference standards anchor continuity after a cell, process, formulation or reference-standard change. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
CHAPTER 13 OF 17 · Sustain comparability
13. Quantity and protein content support dosing and consistency
Suitable physicochemical or other methods measure amount, with awareness of excipients, absorptivity, moisture and method specificity. Quantity is interpreted with potency and purity.
The scientific value of quantity and protein content support dosing and consistency comes from linking knowledge to a defined quality decision. Suitable physicochemical or other methods measure amount, with awareness of excipients, absorptivity, moisture and method specificity. Quantity is interpreted with potency and purity. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
Try this
Build an evidence map for quantity and protein content support dosing and consistency. Trace quantity and protein content support dosing and consistency from molecular or process origin to its safety or efficacy relevance. Add the decision, owner and acceptance criterion. Keep this limit: A single purity method cannot describe every relevant biological variant.
A strong science note separates observation from interpretation. Trace quantity and protein content support dosing and consistency from molecular or process origin to its safety or efficacy relevance. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace quantity and protein content support dosing and consistency from molecular or process origin to its safety or efficacy relevance. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
CHAPTER 14 OF 17 · Sustain comparability
14. Specifications follow characterisation, process and clinical knowledge
Tests and criteria reflect attributes linked to safety and efficacy, observed manufacturing ranges, analytical capability and stability. Limits are not merely the minimum and maximum of early batches.
For specifications follow characterisation, process and clinical knowledge, a useful explanation shows both expected performance and the response to variation. Tests and criteria reflect attributes linked to safety and efficacy, observed manufacturing ranges, analytical capability and stability. Limits are not merely the minimum and maximum of early batches. Preserve this guardrail: Binding activity may not substitute for a functional potency assay when function matters.
Try this
Challenge the assumptions behind specifications follow characterisation, process and clinical knowledge. Use an orthogonal method or functional assay to challenge specifications follow characterisation, process and clinical knowledge. Test a plausible failure mode and record the result. Respect this boundary: Binding activity may not substitute for a functional potency assay when function matters.
A strong science note separates observation from interpretation. Use an orthogonal method or functional assay to challenge specifications follow characterisation, process and clinical knowledge. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Use an orthogonal method or functional assay to challenge specifications follow characterisation, process and clinical knowledge. Keep this boundary visible: Binding activity may not substitute for a functional potency assay when function matters.
CHAPTER 15 OF 17 · Sustain comparability
15. Release and shelf-life criteria can reflect change over time
Some attributes may drift during storage. Release controls provide enough margin for the product to remain within the approved shelf-life standard.
A trustworthy account of release and shelf-life criteria can reflect change over time keeps evidence, assumptions and lifecycle action together. Some attributes may drift during storage. Release controls provide enough margin for the product to remain within the approved shelf-life standard. Remember: Manufacturing consistency alone does not prove every product-related variant is acceptable.
Try this
Audit the lifecycle record for release and shelf-life criteria can reflect change over time. Justify the acceptance criterion for release and shelf-life criteria can reflect change over time using batches, process capability and clinical knowledge. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Manufacturing consistency alone does not prove every product-related variant is acceptable.
A strong science note separates observation from interpretation. Justify the acceptance criterion for release and shelf-life criteria can reflect change over time using batches, process capability and clinical knowledge. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Justify the acceptance criterion for release and shelf-life criteria can reflect change over time using batches, process capability and clinical knowledge. Keep this boundary visible: Manufacturing consistency alone does not prove every product-related variant is acceptable.
CHAPTER 16 OF 17 · Sustain comparability
16. Process changes can alter biological attributes
A new cell bank, culture condition, purification step, formulation or site may change variants or impurities. Q5E comparability and Q5C stability help evaluate the effect.
The scientific value of process changes can alter biological attributes comes from linking knowledge to a defined quality decision. A new cell bank, culture condition, purification step, formulation or site may change variants or impurities. Q5E comparability and Q5C stability help evaluate the effect. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
Try this
Build an evidence map for process changes can alter biological attributes. Reassess process changes can alter biological attributes after a cell, process, formulation or reference-standard change. Add the decision, owner and acceptance criterion. Keep this limit: Routine specifications cannot replace broad characterisation during development and change assessment.
A strong science note separates observation from interpretation. Reassess process changes can alter biological attributes after a cell, process, formulation or reference-standard change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess process changes can alter biological attributes after a cell, process, formulation or reference-standard change. Keep this boundary visible: Routine specifications cannot replace broad characterisation during development and change assessment.
CHAPTER 17 OF 17 · Sustain comparability
17. A complete Q6B receipt connects complexity to control
The record includes characterisation, critical attributes, identity, potency, quantity, variants, process impurities, methods, reference standards, batch and stability data, clinical relevance, acceptance criteria and change triggers. It shows why the routine specification is sufficient.
For a complete q6b receipt connects complexity to control, a useful explanation shows both expected performance and the response to variation. The record includes characterisation, critical attributes, identity, potency, quantity, variants, process impurities, methods, reference standards, batch and stability data, clinical relevance, acceptance criteria and change triggers. It shows why the routine specification is sufficient. Preserve this guardrail: A single purity method cannot describe every relevant biological variant.
Try this
Challenge the assumptions behind a complete q6b receipt connects complexity to control. Trace a complete q6b receipt connects complexity to control from molecular or process origin to its safety or efficacy relevance. Test a plausible failure mode and record the result. Respect this boundary: A single purity method cannot describe every relevant biological variant.
A strong science note separates observation from interpretation. Trace a complete q6b receipt connects complexity to control from molecular or process origin to its safety or efficacy relevance. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace a complete q6b receipt connects complexity to control from molecular or process origin to its safety or efficacy relevance. Keep this boundary visible: A single purity method cannot describe every relevant biological variant.
Q6B biological-specification map
| Question | Evidence to capture | Boundary to retain |
|---|---|---|
| What is the product? | Structure, physicochemical and biological characterisation | Understand complexity first |
| What can vary? | Product-related and process-related species | Separate origins and impacts |
| What is tested routinely? | Identity, purity, potency and quantity | Choose meaningful methods |
| What limits are justified? | Clinical relevance, process range and stability | Maintain lifecycle control |
Science learning becomes useful when a student can show where a claim came from, why it applies and where it stops. Continue with the eduKate Science Learning Hub, compare choices in the Education Hub, and connect these habits to career pathways built from subject capabilities.
Q6B makes a complex biological product controllable without reducing it to one number. Deep characterisation reveals the relevant molecular landscape, and a justified specification selects the tests that best protect identity, purity, potency and consistency.
Primary sources and verification date
Source status checked 26 October 2026. FDA guidance describes the agency’s current thinking and does not replace applicable statutes, regulations or product-specific communication with FDA.
- FDA: Q6B Biological Product Specifications — Final guidance, August 1999.
- FDA: Full Q6B guidance PDF — Official characterisation and specification framework.
- FDA: Pharmaceutical quality document index — Current FDA quality guidance index, checked 26 October 2026.